Back to Dashboard









IQVIA Holdings, Inc. (IQV)
Real-time intraday values
Market Overview
From:
To:
IQV Intraday
No data available
SymbolIQV
IPO DateMay 9, 2013
CEOMr. Ari Bousbib
Full Time Employees94k
SectorHealthcare
IndustryDiagnostics & Research
CountryUnited States
ExchangeNYSE
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.37% | +1.03 US$ |
| 5 Days | +4.66% | +12.45 US$ |
| 1 Month | +4.29% | +11.49 US$ |
| 6 Months | +72.14% | +117.07 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of IQV...
Key Statistics
Market Cap
45.98B
P/E Ratio
34.70
Div Yield
0.00%
52W High
$282.98
52W Low
$154.50
Analyst Consensus
ConsensusStrong Buy
Bullish1990.5%
Neutral29.5%
Bearish00.0%
52W Analyst Price Targets
Min Target
$268.00
$268.00
Max Target
$345.00
$345.00
Current$279.35
Avg Target$302.67
Analyst Recommendations
Target Price:$302.67($268.00 - $345.00)
Community Thoughts
Share your analysis and sentiment on IQV
Join the community to share your analysis
Latest News for IQV

Locking in Gains: Portfolio Discipline Triggers IQVIA Holding (IQV) Trim After Q2 Beat
Insider Monkey•Oct 23, 2026, 04:20 PM

From Headwinds to Full Valuation: The Disciplined Exit of IQVIA Holdings (IQV)
Insider Monkey•Oct 23, 2026, 03:44 PM

Guidance Up, Trend Intact: Veeva Is Today's Double-Confirmation Stock
Trefis•Oct 23, 2026, 08:03 AM

IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
Zacks•Oct 22, 2026, 12:58 PM

Is Veeva Systems Stock Really Expensive?
Trefis•Oct 21, 2026, 02:36 PM

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
Zacks•Oct 21, 2026, 01:00 PM

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
Zacks•Oct 20, 2026, 01:00 PM

Should You Be Worried About Tempus AI Stock?
Trefis•Oct 20, 2026, 11:03 AM

1 Large-Cap Stock to Research Further and 2 We Avoid
StockStory•Oct 19, 2026, 10:16 AM
BMO Capital Adjusts Price Target on IQVIA to $305 From $270
MT Newswires•Oct 19, 2026, 09:55 AM